Literature DB >> 10583523

Assessing health-related quality-of-life in individuals with haemophilia.

A H Miners1, C A Sabin, K H Tolley, C Jenkinson, P Kind, C A Lee.   

Abstract

The objectives of this study were to analyse current levels of health-related quality-of-life (HR-QoL) in individuals with severe haemophilia and to assess the scope for these levels to improve. To do this, 249 individuals with severe, moderate and mild haemophilia were asked to complete Medical Outcomes Study (MOS) Short-Form 36 (SF-36) and EuroQol (EQ-5D) questionnaires. Access was also gained to two appropriate normative data sets. The results from these questionnaires showed that HIV status, history of orthopaedic surgery and bleeding frequency in the previous calendar year were not strong predictors of HR-QoL for individuals with severe haemophilia. However, for the majority of scales, age was found to be a strong predictor of HR-QoL for this patient group. The results from the analysis also showed that compared to individuals with moderate/mild haemophilia and the UK male normative population, individuals with severe haemophilia generally recorded poorer levels of HR-QoL. These results suggest, therefore, that individuals with severe haemophilia have reduced levels of HR-QoL compared to individuals with moderate/mild haemophilia and the general population, irrespective of differences in age. The results also suggest that the scope for primary prophylaxis to increase HR-QoL in individuals with severe haemophilia is significant.

Entities:  

Mesh:

Year:  1999        PMID: 10583523     DOI: 10.1046/j.1365-2516.1999.00347.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  28 in total

1.  Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention.

Authors:  A H Miners; A Holmes; L Sherr; C Jenkinson; K D MacDermot
Journal:  Qual Life Res       Date:  2002-03       Impact factor: 4.147

Review 2.  Quality of life in rare genetic conditions: a systematic review of the literature.

Authors:  Julie S Cohen; Barbara B Biesecker
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

3.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

Authors:  Peter W Collins; Guy Young; Karin Knobe; Faraizah Abdul Karim; Pantep Angchaisuksiri; Claus Banner; Türkiz Gürsel; Johnny Mahlangu; Tadashi Matsushita; Eveline P Mauser-Bunschoten; Johannes Oldenburg; Christopher E Walsh; Claude Negrier
Journal:  Blood       Date:  2014-09-26       Impact factor: 22.113

4.  The importance of genetic factors for the development of arthropathy: a longitudinal study of children and adolescents with haemophilia A.

Authors:  Edward D Gomperts; John Schwarz; Sharyne M Donfield; Alice E Lail; Jan Astermark; W Keith Hoots; Cheryl A Winkler; Erik Berntorp
Journal:  Thromb Haemost       Date:  2016-12-08       Impact factor: 5.249

Review 5.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

6.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

7.  Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.

Authors:  Alexander H Miners; Caroline A Sabin; Keith H Tolley; Christine A Lee
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Health-related quality of life measures in genetic disorders: an outcome variable for consideration in clinical trials.

Authors:  David A Stevenson; John C Carey
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-08-15       Impact factor: 3.908

9.  Assessing quality of life in individuals with hereditary blood coagulation disorders.

Authors:  S Solovieva; N Santavirta; S Santavirta; Y T Konttinen
Journal:  Qual Life Res       Date:  2004-06       Impact factor: 4.147

10.  Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.

Authors:  Steven Pipe
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.